The Use of Antidepressant Drugs in Climacteric Syndrome

References
1 Pinkerton JV, Sánchez Aguirre F, Blake J, Cosman F, Hodis HN, Hoffstetter S. et al. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017; 24 (07) 728-753 . doi: 10.1097/GME.0000000000000921
2 Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB. et al. Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015; 175 (04) 531-539 . doi: 10.1001/jamainternmed.2014.8063
3 Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD. et al; Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010; 95 (07) (Suppl. 01) s1-s66 . doi: 10.1210/jc.2009-2509
4 Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004; (04) CD002978 . doi: 10.1002/14651858.CD002978.pub2
5 Santen RJ, Loprinzi CL, Casper RF. Menopausal hot flashes [Internet]. UpToDate; 2016 [2019 May 12]. Available from: https://www.uptodate.com/contents/menopausal-hot-flashes
6 Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H. et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011; 305 (03) 267-274 . doi: 10.1001/jama.2010.2016
7 [No authors listed]. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015; 22 (11) 1155-1172 , quiz 1173–1174. doi: 10.1097/GME.0000000000000546
8 Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002; 360 (9348): 1851-1861 . doi: 10.1016/s0140-6736(02)11774-0
9 Wiśniewska I, Jochymek B, Lenart-Lipińska M, Chabowski M. The pharmacological and hormonal therapy of hot flushes in breast cancer survivors. Breast Cancer 2016; 23 (02) 178-182 . doi: 10.1007/s12282-015-0655-2
10 Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin N. 126: Management of gynecologic issues in women with breast cancer. Obstet Gynecol 2012; 119 (03) 666-682 . doi: 10.1097/AOG.0b013e31824e12ce
11 Handley AP, Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract 2015; 27 (01) 54-61 . doi: 10.1002/2327-6924.12137
12 Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA. , et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002; 20 (06) 1578-1583 . doi: 10.1200/JCO.2002.20.6.1578
13 Takahashi TA, Johnson KM. Menopause. Med Clin North Am 2015; 99 (03) 521-534 . doi: 10.1016/j.mcna.2015.01.006
14 Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006; 12 (02) 114-122 . doi: 10.1111/j.1075-122X.2006.00218.x
15 Irarrázaval O ME, Gaete G L. [Antidepressants agents in breast cancer patients using tamoxifen: review of basic and clinical evidence]. Rev Med Chil 2016; 144 (10) 1326-1335 . doi: 10.4067/S0034-98872016001000013
16 Leon-Ferre RA, Majithia N, Loprinzi CL. Management of hot flashes in women with breast cancer receiving ovarian function suppression. Cancer Treat Rev 2017; 52: 82-90 . doi: 10.1016/j.ctrv.2016.11.012
17 Shams T, Firwana B, Habib F. , et al. SSRIs for hot flashes: a systematic review and meta-analysis of randomized trials. J Gen Intern Med 2014; 29 (01) 204-213 . doi: 10.1007/s11606-013-2535-9
18 L'Espérance S, Frenette S, Dionne A, Dionne JY. ; Comité de l'évolution des pratiques en oncologie (CEPO). Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer 2013; 21 (05) 1461-1474 . doi: 10.1007/s00520-013-1732-8
19 Al-Safi ZA, Santoro N. Menopausal hormone therapy and menopausal symptoms. Fertil Steril 2014; 101 (04) 905-915 . doi: 10.1016/j.fertnstert.2014.02.032
20 Simon JA, Portman DJ, Kaunitz AM. , et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013; 20 (10) 1027-1035 . doi: 10.1097/GME.0b013e3182a66aa7
21 Pinkerton JV, Joffe H, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause. Menopause 2015; 22 (01) 50-58 . doi: 10.1097/GME.0000000000000311
22 Capriglione S, Plotti F, Montera R, Luvero D, Lopez S, Scaletta G. , et al. Role of paroxetine in the management of hot flashes in gynecological cancer survivors: Results of the first randomized single-center controlled trial. Gynecol Oncol 2016; 143 (03) 584-588 . doi: 10.1016/j.ygyno.2016.10.006
23 Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA, Edin HM. Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry 2006; 67 (02) 204-210
24 Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry 2001; 62 (Suppl. 03) 10-21
25 Basson R, Schultz WW. Sexual sequelae of general medical disorders. Lancet 2007; 369 (9559): 409-424 . doi: 10.1016/S0140-6736(07)60197-4
26 Stubbs C, Mattingly L, Crawford SA, Wickersham EA, Brockhaus JL, McCarthy LH. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. J Okla State Med Assoc 2017; 110 (05) 272-274
27 Heerlein A. Antidepressant pharmacologic treatments. Rev Chil Neuro-psiquiatr 2002; 40 (Suppl. 01) 21-45 . doi: 10.4067/S0717-92272002000500003
28 Olié JP, Elomari F, Spadone C, Lépine JP. [Antidepressants consumption in the global population in France]. Encephale 2002; 28 (5 Pt 1): 411-417
29 Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009; 66 (08) 848-856 . doi: 10.1001/archgenpsychiatry.2009.81
30 Verhaak PFM, de Beurs D, Spreeuwenberg P. What proportion of initially prescribed antidepressants is still being prescribed chronically after 5 years in general practice? A longitudinal cohort analysis. BMJ Open 2019; 9 (02) e024051 . doi: 10.1136/bmjopen-2018-024051
31 Mars B, Heron J, Kessler D, Davies NM, Martin RM, Thomas KH, Gunnell D. Influences on antidepressant prescribing trends in the UK: 1995-2011. Soc Psychiatry Psychiatr Epidemiol 2017; 52 (02) 193-200 . doi: 10.1007/s00127-016-1306-4
32 Andrews PW, Thomson Jr JA, Amstadter A, Neale MC. Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Front Psychol 2012; 3: 117 . doi: 10.3389/fpsyg.2012.00117
33 Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003; 289 (21) 2827-2834 . doi: 10.1001/jama.289.21.2827
34 Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011; 343: d4551 . doi: 10.1136/bmj.d4551
35 Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H. , et al. Use of mental health services in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004; (420) 47-54 . doi: 10.1111/j.1600-0047.2004.00330.x
36 Meijer WEE, Heerdink ER, Leufkens HGM, Herings RMC, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004; 60 (01) 57-61 . doi: 10.1007/s00228-004-0726-3
37 Johnson CF, Macdonald HJ, Atkinson P, Buchanan AI, Downes N, Dougall N. Reviewing long-term antidepressants can reduce drug burden: a prospective observational cohort study. Br J Gen Pract 2012; 62 (604) e773-e779 . doi: 10.3399/bjgp12X658304
38 Petty DR, House A, Knapp P, Raynor T, Zermansky A. Prevalence, duration and indications for prescribing of antidepressants in primary care. Age Ageing 2006; 35 (05) 523-526 . doi: 10.1093/ageing/afl023
39 Mojtabai R, Olfson M. National trends in long-term use of antidepressant medications: results from the U.S. National Health and Nutrition Examination Survey. J Clin Psychiatry 2014; 75 (02) 169-177 . doi: 10.4088/JCP.13m08443
40 Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol 2013; 23 (11) 1443-1451 . doi: 10.1016/j.euroneuro.2013.05.001
41 Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ. ; WFSBP Task Force on Treatment Guidelines for Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disoders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008; 9 (04) 248-312 . doi: 10.1080/15622970802465807
42 Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ. , et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 2015; 29 (05) 459-525 . doi: 10.1177/0269881115581093
43 Johnson CF, Williams B, MacGillivray SA, Dougall NJ, Maxwell M. ‘Doing the right thing’: factors influencing GP prescribing of antidepressants and prescribed doses. BMC Fam Pract 2017; 18 (01) 72 . doi: 10.1186/s12875-017-0643-z
44 Bosman RC, Huijbregts KM, Verhaak PF, Ruhé HG, van Marwijk HW, van Balkom AJ, Batelaan NM. Long-term antidepressant use: a qualitative study on perspectives of patients and GPs in primary care. Br J Gen Pract 2016; 66 (651) e708-e719 . doi: 10.3399/bjgp16X686641
45 Mintziori G, Lambrinoudaki I, Goulis DG, Ceausu I, Depypere H, Erel CT. et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms. Maturitas 2015; 81 (03) 410-413 . doi: 10.1016/j.maturitas.2015.04.009